ClinicalTrials.gg
CompletedNCT03191799STASEYUpdated Jun 11, 2021Results posted

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

A Phase 3 interventional study of Emicizumab in Hemophilia A, sponsored by Hoffmann-La Roche. Completed at 72 sites in 24 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
195
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.

Enrollment
Largest of 22
195 · median 27
Started
2017
with 1 other
Phase 3
11 of 22
none open now
Registered
5th of 22
by date
Lead sponsor
10 of 22
Hoffmann-La Roche

Among the 22 studies testing emicizumab in Hemophilia A, this one has the largest enrollment, is one of 2 that started in 2017, is one of 11 in phase 3, and was the 5th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About emicizumab

emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing emicizumab in Hemophilia A, or all of them as a file.
02

Study summary

This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and tolerability of emicizumab in participants with congenital hemophilia A who have documented inhibitors against Factor VIII (FVIII) at enrollment. Approximately 200 participants, aged 12 or older, will be enrolled in this study and are expected to be enrolled at approximately 85 sites globally. Participants will receive an initial weekly dose of prophylactic emicizumab subcutaneously for 4 weeks, followed by a weekly maintenance dose subcutaneously for the remainder of the 2-year treatment period.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • As per investigator's judgement, a willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including the patient-reported outcome (PRO) questionnaires and bleed diaries through the use of an electronic device or paper
  • Aged 12 years or older at the time of
  • Diagnosis of congenital hemophilia A with persistent inhibitors against FVIII
  • Documented treatment with bypassing agents or FVIII concentrates in the last 6 months (on-demand or prophylaxis). Prophylaxis needs to be discontinued the latest by a day before starting emicizumab
  • Adequate hematologic, hepatic, and renal function
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use a highly effective method with a failure rate of \<1% per year during the treatment period and for at least five elimination half-lives (24 weeks) after the last dose of emicizumab

Exclusion criteria

Exclusion Criteria:

  • Inherited or acquired bleeding disorder other than hemophilia A
  • Ongoing (or plan to receive during the study) immune tolerance induction (ITI) therapy (prophylaxis regimens with FVIII and/or bypassing agents must be discontinued prior to enrollment). Patients receiving ITI therapy will be eligible following the completion of a 72-hour prior to the first emicizumab administration
  • History of illicit drug or alcohol abuse within 12 months prior to screening, as per the investigator's judgment
  • High risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA), as per the investigator's judgment
  • Previous (in the past 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which antithrombotic treatment is not currently ongoing) or current signs of thromboembolic disease
  • Other conditions (e.g., certain diseases) that may increase the risk of bleeding or thrombosis
  • History of reaction associated with monoclonal antibody therapies or components of the emicizumab injection
  • Known (HIV) infection with \<200 cells/μL within 6 months prior to screening
  • Use of systemic immunomodulators (e.g., interferon or rituximab) at enrollment or planned use during the study, with the exception of antiretroviral therapy
  • Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the patient's safe participation in and completion of the study or interpretation of the study results
  • Receipt of: Emicizumab in a prior study; An investigational drug to treat or reduce the risk of hemophilic bleeds within five half-lives of last drug administration; A non-hemophilia-related investigational drug within last 30 days or five half-lives, whichever is shorter; or, Any concurrent investigational drug.
  • Pregnancy or lactation, or intent to become pregnant during the study
  • Positive serum pregnancy test result within 7 days prior to initiation of emicizumab (females only)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    1.5 mg/kg Emicizumab QW

    Participants will receive initial weekly doses of prophylactic emicizumab subcutaneously for 4 weeks, followed by maintenance doses consisting of half the initial dose, administered subcutaneously for the remainder of the 2-year treatment period

    Drug: Emicizumab

Interventions

  • Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period

    Also known as: Hemlibra, RO5534262, ACE910

06

What researchers measure

Primary outcomes

  1. Overall Summary of the Number of Participants With Adverse Events, Severity Assessed According to the World Health Organization (WHO) Toxicity Grading Scale

    Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. aPCC = activated prothrombin complex concentrate

    Time frame: From Baseline until study completion (up to 2 years)

  2. Adverse Events (AEs) Rates Per 100 Patient-Years for All-Grade AEs, Serious AEs, and Grade ≥3 AEs

    Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. The AE rate per 100 patient-years was computed as follows: AE Rate = (Number of AEs observed/ Total patient-years at risk)\*100. Total patient-years at risk is the sum over all patients of the time intervals (in years) between start of study therapy (study day 1) and the end of follow up.

    Time frame: From Baseline until study completion (up to 2 years)

  3. Number of Participants by Hematology and Biochemistry Laboratory Parameter Test Results as Shifts From the WHO Toxicity Grade at Baseline to the Worst WHO Toxicity Grade Post-Baseline

    The World Health Organization (WHO) toxicity grading scale was used for determining the severity of laboratory abnormalities (i.e., test results outside of the reference range) for hematology and biochemistry parameters; Grade 0 is normal and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. Baseline was defined as the last available assessment prior to first receipt of study drug. Abs = absolute count; SGOT/AST = aspartate aminotransferase; SGPT/ALT = alanine aminotransferase

    Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)

  4. Change From Baseline in Body Temperature at Specified Timepoints

    Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

    Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)

  5. Change From Baseline in Systolic Blood Pressure at Specified Timepoints

    Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

    Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)

  6. Change From Baseline in Diastolic Blood Pressure at Specified Timepoints

    Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

    Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)

  7. Change From Baseline in Pulse Rate at Specified Timepoints

    Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

    Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)

  8. Change From Baseline in Respiratory Rate at Specified Timepoints

    Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

    Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)

  9. Change From Baseline in Body Weight at Specified Timepoints

    Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

    Time frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)

Secondary outcomes

  1. Model-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds

    The number of bleeds over the efficacy period was analyzed as an ABR using a negative binomial regression model. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all bleed types, bleeds due to surgery/procedure were excluded. Bleeds occurring after dose up-titration have been excluded.

    Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)

  2. Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds

    The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all types, bleeds due to surgery/procedure and bleeds occurring after dose up-titration were excluded.

    Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)

  3. Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds

    The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all types, bleeds due to surgery/procedure and bleeds occurring after dose up-titration were excluded.

    Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)

  4. Percentage of Participants by the Categorized Number of Bleeds for Treated Bleeds

    Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

    Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)

  5. Percentage of Participants by the Categorized Number of Bleeds for All Bleeds

    All bleeds: included both treated and non-treated bleeds. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

    Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)

  6. Percentage of Participants by the Categorized Number of Bleeds for Treated Spontaneous Bleeds

    Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

    Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)

  7. Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for Treated Bleeds

    The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

    Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)

  8. Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for All Bleeds

    The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds: included both treated and non-treated bleeds. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

    Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)

  9. Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds

    The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

    Time frame: From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)

  10. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Total Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. The Total Score is based on the scores for each domain and ranges from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  11. Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Total Score at Specified Timepoints

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. The Total Score is based on the scores for each domain and ranges from 0 to 100, with lower scores reflective of better quality of life. An improvement larger than the responder threshold was defined as a decrease from baseline of at least 7 points in the Haem-A-QoL Total score.

    Time frame: At 3, 6, 12, and 18 months

  12. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Physical Health Domain Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  13. Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Physical Health Domain Score at Specified Timepoints

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life. An improvement larger than the responder threshold was defined as a decrease from baseline of at least 10 points in the Haem-A-QoL Physical Health domain score.

    Time frame: At 3, 6, 12, and 18 months

  14. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Treatment Domain Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  15. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Work and School Domain Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  16. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Dealing With Hemophilia Domain Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  17. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Feelings Domain Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  18. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Family Planning Domain Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  19. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Future Domain Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  20. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Partnership and Sexuality Domain Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  21. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Sports and Leisure Domain Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  22. Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire View of Yourself Domain Score at Specified Timepoints, Adult Participants

    The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  23. Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score at Specified Timepoints, Adolescent Participants

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. The Total Score is derived from the scores for all domains and scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  24. Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score at Specified Timepoints

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. The Total Score is derived from the scores for all domains and scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life. An improvement larger than the responder threshold was defined as a decrease of at least 5 points in the Haemo-QoL-SF Total score.

    Time frame: At 3, 6, 12, and 18 months

  25. Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Physical Health Domain Score at Specified Timepoints, Adolescent Participants

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  26. Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Physical Health Domain Score at Specified Timepoints

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life. An improvement larger than the responder threshold was defined as a decrease of at least 10 points in the Haemo-QoL-SF Physical Health domain score.

    Time frame: At 3, 6, 12, and 18 months

  27. Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Treatment Domain Score at Specified Timepoints, Adolescent Participants

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  28. Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Sports and School Domain Score at Specified Timepoints, Adolescent Participants

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  29. Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Dealing With Hemophilia Domain Score at Specified Timepoints, Adolescent Participants

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  30. Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Feelings Domain Score at Specified Timepoints, Adolescent Participants

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  31. Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Family Domain Score at Specified Timepoints, Adolescent Participants

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  32. Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Friends Domain Score at Specified Timepoints, Adolescent Participants

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  33. Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Other People Domain Score at Specified Timepoints, Adolescent Participants

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  34. Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire View of Yourself Domain Score at Specified Timepoints, Adolescent Participants

    The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  35. Change From Baseline in the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) Index Utility Score at Specified Timepoints

    The EQ-5D-5L is a generic, self-reported, preference-based health utility measure that consists of six questions and is used to assess health status and inform pharmacoeconomic evaluations. The index utility score is based on the participant's assessment of their health on five scales: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It ranges from -0.224 to 1, with 0 corresponding to death and 1 corresponding to full health; negative values correspond to health states worse than death. Higher scores indicate better quality of life.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  36. Change From Baseline in the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) Quality-of-Life Visual Analogue Scale (VAS) Score at Specified Timepoints

    The EQ-5D-5L is a generic, self-reported, preference-based health utility measure that consists of six questions and is used to assess health status and inform pharmacoeconomic evaluations. The visual analogue scale (VAS) ranges from 0 to 100 points, on which the participant self-assesses their current health status; 0 being the worst health you can imagine and 100 being the best health you can imagine. Higher scores are reflective of better health.

    Time frame: Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)

  37. Percentage of Participants Who Preferred the New Emicizumab Treatment or the Old Hemophilia Treatment, or Without Treatment Preference, as Assessed by the EmiPref Questionnaire

    The EmiPref questionnaire asked participants to specify the treatment they would prefer to continue to receive after receiving treatment with their previous episodic or prophylactic regimen and subcutaneous (SC) emicizumab, or if they had no preference. The 95% confidence intervals were calculated for one sample binomial using the Pearson-Clopper method.

    Time frame: Month 3

  38. Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) Against Emicizumab at Anytime Post-Baseline

    'Total ADA Negative' is the sum of all subjects who tested negative for ADA in the 2 following categories: 'ADA Negative', those who are pre-dose ADA negative or are missing pre-dose ADA data and who have all negative post-dose ADA results; and 'ADA Negative (Treatment Unaffected)', a subset who are pre-dose ADA positive but do not have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample.

    Time frame: Baseline (Week 1), Week 5, and at 3, 6, 9, 12, and 18 months, and at early termination/study completion (up to 24 months)

  39. Mean Trough Plasma Concentrations of Emicizumab at Specified Timepoints

    The trough concentration is a measure of the plasma concentration of a study drug at the end of of the dosage interval.

    Time frame: Pre-dose at Weeks 2, 3, and 5, Months 3, 6, 12, and 18, and at treatment discontinuation (up to 2 years)

07

Results

Posted Jun 11, 2021

Participant flow

Participant flow — Overall Study
Milestone1.5 mg/kg Emicizumab QW
Started195
Received at least one dose of emicizumab193
Dose up-titrated to 3 mg/kg qw2
Completed186
Not completed9
Withdrew: Withdrawal by subject4
Withdrew: Physician decision2
Withdrew: Lost to follow-up1
Withdrew: Death2

Outcome measures

PrimaryOverall Summary of the Number of Participants With Adverse Events, Severity Assessed According to the World Health Organization (WHO) Toxicity Grading Scale

Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. aPCC = activated prothrombin complex concentrate

Time frame:
From Baseline until study completion (up to 2 years)
Reported as:
Count of participants · Participants
Overall Summary of the Number of Participants With Adverse Events, Severity Assessed According to the World Health Organization (WHO) Toxicity Grading Scale
Participants1.5 mg/kg Emicizumab QW
Any Adverse Event (AE)163
Fatal AE2
Serious AE31
AE Leading to Withdrawal from Treatment1
AE Leading to Dose Modification/Interruption4
AE Leading to Study Discontinuation1
Grade 3-5 AE39
Related AE35
Local Injection Site Reaction22
Systemic Hypersensitivity/Anaphylac(tic/toid) Reaction0
Thromboembolic Event (TE)2
TE Related to aPCC and Emicizumab0
Thrombotic Microangiopathy (TMA)0
TMA Related to aPCC and Emicizumab0
Cases of Potential Drug-Induced Liver Injury0
Suspected Transmission of Infectious Agent by the Study Drug0
PrimaryAdverse Events (AEs) Rates Per 100 Patient-Years for All-Grade AEs, Serious AEs, and Grade ≥3 AEs

Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. The AE rate per 100 patient-years was computed as follows: AE Rate = (Number of AEs observed/ Total patient-years at risk)\*100. Total patient-years at risk is the sum over all patients of the time intervals (in years) between start of study therapy (study day 1) and the end of follow up.

Time frame:
From Baseline until study completion (up to 2 years)
Reported as:
Number · AEs per 100 patient-years
Adverse Events (AEs) Rates Per 100 Patient-Years for All-Grade AEs, Serious AEs, and Grade ≥3 AEs
AEs per 100 patient-years1.5 mg/kg Emicizumab QW
All-Grade AEs211.92 (197.49 to 227.13)
Serious AEs13.25 (9.83 to 17.46)
Grade ≥3 AEs17.22 (13.29 to 21.95)
PrimaryNumber of Participants by Hematology and Biochemistry Laboratory Parameter Test Results as Shifts From the WHO Toxicity Grade at Baseline to the Worst WHO Toxicity Grade Post-Baseline

The World Health Organization (WHO) toxicity grading scale was used for determining the severity of laboratory abnormalities (i.e., test results outside of the reference range) for hematology and biochemistry parameters; Grade 0 is normal and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. Baseline was defined as the last available assessment prior to first receipt of study drug. Abs = absolute count; SGOT/AST = aspartate aminotransferase; SGPT/ALT = alanine aminotransferase

Time frame:
Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Reported as:
Count of participants · Participants
Number of Participants by Hematology and Biochemistry Laboratory Parameter Test Results as Shifts From the WHO Toxicity Grade at Baseline to the Worst WHO Toxicity Grade Post-Baseline
Participants1.5 mg/kg Emicizumab QW
Hemoglobin, Low - Grade 0 to 0173
Hemoglobin, Low - Grade 0 to 18
Hemoglobin, Low - Grade 0 to 24
Hemoglobin, Low - Grade 0 to 41
Hemoglobin, Low - Grade 1 to 01
Hemoglobin, Low - Grade 1 to 12
Hemoglobin, Low - Grade 1 to 21
Hemoglobin, Low - Grade 1 to 31
Hemoglobin, Low - Grade 2 to 11
Hemoglobin, Low - Grade 2 to 31
Neutrophils, Total (Abs), Low - Grade 0 to 0173
Neutrophils, Total (Abs), Low - Grade 0 to 113
Neutrophils, Total (Abs), Low - Grade 0 to 21
Neutrophils, Total (Abs), Low - Grade 0 to 32
Neutrophils, Total (Abs), Low - Grade 0 to 42
Neutrophils, Total (Abs), Low - Grade 1 to 12
Platelets, Low - Grade 0 to 0190
Platelets, Low - Grade 0 to 12
Platelets, Low - Grade 1 to 01
Alkaline Phosphatase, High - Grade 0 to 0187
Alkaline Phosphatase, High - Grade 0 to 13
Alkaline Phosphatase, High - Grade 0 to 21
Alkaline Phosphatase, High - Grade 1 to 12
Bilirubin, High - Grade 0 to 0169
Bilirubin, High - Grade 0 to 114
Bilirubin, High - Grade 1 to 03
Bilirubin, High - Grade 1 to 12
Bilirubin, High - Grade 1 to 23
Bilirubin, High - Grade 2 to 22
Blood Urea Nitrogen, High - Grade 0 to 0187
Blood Urea Nitrogen, High - Grade 0 to 15
Blood Urea Nitrogen, High - Grade 1 to 11
Calcium (Corrected), High - Grade 0 to 0192
Calcium (Corrected), High - Grade 1 to 21
Calcium (Corrected), Low - Grade 0 to 0173
Calcium (Corrected), Low - Grade 0 to 115
Calcium (Corrected), Low - Grade 0 to 21
Calcium (Corrected), Low - Grade 1 to 03
Calcium (Corrected), Low - Grade 1 to 11
Creatinine, High - Grade 0 to 0185
Creatinine, High - Grade 0 to 15
Creatinine, High - Grade 0 to 21
Creatinine, High - Grade 1 to 11
Creatinine, High - Grade 1 to 21
Glucose, High - Grade 0 to 0148
Glucose, High - Grade 0 to 128
Glucose, High - Grade 0 to 26
Glucose, High - Grade 1 to 12
Glucose, High - Grade 1 to 23
Glucose, High - Grade 2 to 21
Glucose, High - Grade 2 to 31
Glucose, High - Grade 3 to 21
Glucose, High - Grade 3 to 32
Glucose, High - Grade 4 to 31
Glucose, Low - Grade 0 to 0180
Glucose, Low - Grade 0 to 17
Glucose, Low - Grade 0 to 24
Glucose, Low - Grade 1 to 02
Magnesium, Low - Grade 0 to 0188
Magnesium, Low - Grade 0 to 14
Magnesium, Low - Grade 1 to 11
Phosphorus, Low - Grade 0 to 0160
Phosphorus, Low - Grade 0 to 121
Phosphorus, Low - Grade 1 to 02
Phosphorus, Low - Grade 1 to 19
Phosphorus, Low - Grade 1 to 21
Potassium, High - Grade 0 to 0189
Potassium, High - Grade 0 to 12
Potassium, High - Grade 0 to 21
Potassium, High - Grade 0 to 41
Potassium, Low - Grade 0 to 0184
Potassium, Low - Grade 0 to 16
Potassium, Low - Grade 1 to 03
SGOT/AST, High - Grade 0 to 0164
SGOT/AST, High - Grade 0 to 113
SGOT/AST, High - Grade 0 to 28
SGOT/AST, High - Grade 1 to 01
SGOT/AST, High - Grade 1 to 15
SGOT/AST, High - Grade 1 to 21
SGOT/AST, High - Grade 1 to 31
SGPT/ALT, High - Grade 0 to 0158
SGPT/ALT, High - Grade 0 to 122
SGPT/ALT, High - Grade 0 to 25
SGPT/ALT, High - Grade 1 to 01
SGPT/ALT, High - Grade 1 to 14
SGPT/ALT, High - Grade 1 to 22
SGPT/ALT, High - Grade 1 to 41
Sodium, High - Grade 0 to 0178
Sodium, High - Grade 0 to 17
Sodium, High - Grade 0 to 22
Sodium, High - Grade 1 to 04
Sodium, High - Grade 1 to 12
Sodium, Low - Grade 0 to 0166
Sodium, Low - Grade 0 to 119
Sodium, Low - Grade 0 to 22
Sodium, Low - Grade 1 to 03
Sodium, Low - Grade 1 to 12
Sodium, Low - Grade 1 to 21
PrimaryChange From Baseline in Body Temperature at Specified Timepoints

Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

Time frame:
Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Reported as:
Mean · degrees Celsius
Change From Baseline in Body Temperature at Specified Timepoints
degrees Celsius1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit36.33 ± 0.52
Change from BL at Week 20.04 ± 0.41
Change from BL at Week 30.03 ± 0.40
Change from BL at Week 50.03 ± 0.45
Change from BL at Month 30.04 ± 0.45
Change from BL at Month 60.07 ± 0.50
Change from BL at Month 90.06 ± 0.48
Change from BL at Month 120.07 ± 0.48
Change from BL at Month 180.10 ± 0.53
Change from BL at Early Termination/Study Completion0.08 ± 0.48
PrimaryChange From Baseline in Systolic Blood Pressure at Specified Timepoints

Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

Time frame:
Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Reported as:
Mean · millimetres of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure at Specified Timepoints
millimetres of mercury (mmHg)1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit121.1 ± 14.3
Change from BL at Week 2-0.9 ± 11.1
Change from BL at Week 3-1.2 ± 10.6
Change from BL at Week 5-1.3 ± 12.3
Change from BL at Month 30.1 ± 11.5
Change from BL at Month 6-0.2 ± 13.1
Change from BL at Month 90.1 ± 13.1
Change from BL at Month 120.1 ± 13.9
Change from BL at Month 18-0.1 ± 13.8
Change from BL at Early Termination/Study Completion1.9 ± 14.1
PrimaryChange From Baseline in Diastolic Blood Pressure at Specified Timepoints

Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

Time frame:
Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Reported as:
Mean · millimetres of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure at Specified Timepoints
millimetres of mercury (mmHg)1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit75.5 ± 10.4
Change from BL at Week 2-1.2 ± 8.5
Change from BL at Week 3-1.0 ± 8.9
Change from BL at Week 5-1.2 ± 9.2
Change from BL at Month 3-0.3 ± 9.8
Change from BL at Month 6-0.7 ± 10.1
Change from BL at Month 9-1.3 ± 9.4
Change from BL at Month 12-1.2 ± 10.4
Change from BL at Month 18-0.9 ± 9.6
Change from BL at Early Termination/Study Completion0.0 ± 11.0
PrimaryChange From Baseline in Pulse Rate at Specified Timepoints

Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

Time frame:
Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Reported as:
Mean · beats per minute
Change From Baseline in Pulse Rate at Specified Timepoints
beats per minute1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit76.6 ± 11.6
Change from BL at Week 21.0 ± 9.9
Change from BL at Week 31.6 ± 11.6
Change from BL at Week 5-0.5 ± 11.3
Change from BL at Month 3-0.8 ± 10.4
Change from BL at Month 6-0.7 ± 11.6
Change from BL at Month 9-1.0 ± 11.3
Change from BL at Month 12-0.5 ± 12.2
Change from BL at Month 18-2.1 ± 12.7
Change from BL at Early Termination/Study Completion-1.2 ± 11.9
PrimaryChange From Baseline in Respiratory Rate at Specified Timepoints

Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

Time frame:
Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Reported as:
Mean · breaths per minute
Change From Baseline in Respiratory Rate at Specified Timepoints
breaths per minute1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit17.0 ± 3.1
Change from BL at Week 20.2 ± 2.2
Change from BL at Week 30.0 ± 2.3
Change from BL at Week 5-0.1 ± 2.5
Change from BL at Month 30.3 ± 4.7
Change from BL at Month 6-0.1 ± 2.5
Change from BL at Month 90.0 ± 2.7
Change from BL at Month 120.3 ± 2.9
Change from BL at Month 18-0.4 ± 2.7
Change from BL at Early Termination/Study Completion-0.7 ± 3.1
PrimaryChange From Baseline in Body Weight at Specified Timepoints

Vital signs that were measured included body temperature, pulse and respiratory rates, systolic and diastolic blood pressure, and weight. On treatment days, measurement occurred prior to emicizumab administration.

Time frame:
Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Reported as:
Mean · kilograms (kg)
Change From Baseline in Body Weight at Specified Timepoints
kilograms (kg)1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit69.55 ± 16.60
Change from BL at Week 20.14 ± 1.06
Change from BL at Week 30.34 ± 1.18
Change from BL at Week 50.52 ± 1.56
Change from BL at Month 30.98 ± 2.44
Change from BL at Month 61.11 ± 3.20
Change from BL at Month 91.61 ± 4.08
Change from BL at Month 121.85 ± 4.88
Change from BL at Month 182.58 ± 5.56
Change from BL at Early Termination/Study Completion3.15 ± 6.78
SecondaryModel-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds

The number of bleeds over the efficacy period was analyzed as an ABR using a negative binomial regression model. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all bleed types, bleeds due to surgery/procedure were excluded. Bleeds occurring after dose up-titration have been excluded.

Time frame:
From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Reported as:
Number · bleeds per year
Model-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds
bleeds per year1.5 mg/kg Emicizumab QW
Treated Bleeds0.5 (0.27 to 0.89)
All Bleeds1.1 (0.80 to 1.47)
Treated Joint Bleeds0.4 (0.15 to 0.86)
Treated Target Joint Bleeds0.2 (0.07 to 0.68)
Treated Spontaneous Bleeds0.3 (0.15 to 0.73)
SecondaryMean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds

The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all types, bleeds due to surgery/procedure and bleeds occurring after dose up-titration were excluded.

Time frame:
From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Reported as:
Mean · bleeds per year
Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds
bleeds per year1.5 mg/kg Emicizumab QW
Treated Bleeds0.6 (0.00 to 4.85)
All Bleeds1.3 (0.06 to 6.02)
Treated Joint Bleeds0.4 (0.00 to 4.55)
Treated Target Joint Bleeds0.3 (0.00 to 4.28)
Treated Spontaneous Bleeds0.4 (0.00 to 4.49)
SecondaryMedian Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds

The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". All bleeds: included both treated and non-treated bleeds. Treated joint bleeds: treated bleeds where bleed type was "joint bleed" accompanied by at least one of following symptoms: "increased swelling or warmth of the skin over the joint", "increasing pain" or "decreased range of motion or difficulty using the joint compared with baseline". Treated target joint bleeds: treated joint bleeds that occurred in a target joint, defined as a joint in which ≥3 treated joint bleeds occurred during the 24 weeks prior to study entry. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. For all types, bleeds due to surgery/procedure and bleeds occurring after dose up-titration were excluded.

Time frame:
From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Reported as:
Median · bleeds per year
Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds
bleeds per year1.5 mg/kg Emicizumab QW
Treated Bleeds0.0 (0.00 to 0.00)
All Bleeds0.0 (0.00 to 1.01)
Treated Joint Bleeds0.0 (0.00 to 0.00)
Treated Target Joint Bleeds0.0 (0.00 to 0.00)
Treated Spontaneous Bleeds0.0 (0.00 to 0.00)
SecondaryPercentage of Participants by the Categorized Number of Bleeds for Treated Bleeds

Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

Time frame:
From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants by the Categorized Number of Bleeds for Treated Bleeds
Percentage of participants1.5 mg/kg Emicizumab QW
0 Bleeds82.6 (76.5 to 87.6)
1-3 Bleeds12.3 (8.0 to 17.8)
4-10 Bleeds4.1 (1.8 to 7.9)
>10 Bleeds1.0 (0.1 to 3.7)
SecondaryPercentage of Participants by the Categorized Number of Bleeds for All Bleeds

All bleeds: included both treated and non-treated bleeds. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

Time frame:
From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants by the Categorized Number of Bleeds for All Bleeds
Percentage of participants1.5 mg/kg Emicizumab QW
0 Bleeds54.9 (47.6 to 62.0)
1-3 Bleeds30.3 (23.9 to 37.2)
4-10 Bleeds12.3 (8.0 to 17.8)
>10 Bleeds2.6 (0.8 to 5.9)
SecondaryPercentage of Participants by the Categorized Number of Bleeds for Treated Spontaneous Bleeds

Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

Time frame:
From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants by the Categorized Number of Bleeds for Treated Spontaneous Bleeds
Percentage of participants1.5 mg/kg Emicizumab QW
0 Bleeds89.2 (84.0 to 93.2)
1-3 Bleeds8.7 (5.2 to 13.6)
4-10 Bleeds1.5 (0.3 to 4.4)
>10 Bleeds0.5 (0.0 to 2.8)
SecondaryPercentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for Treated Bleeds

The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: bleeds followed by a hemophilia medication reported to be a "Treatment for bleed". Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

Time frame:
From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for Treated Bleeds
Percentage of participants1.5 mg/kg Emicizumab QW
ABR <190.3 (85.2 to 94.0)
ABR 1-3.46.2 (3.2 to 10.5)
ABR 3.5-102.6 (0.8 to 5.9)
ABR >101.0 (0.1 to 3.7)
SecondaryPercentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for All Bleeds

The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds: included both treated and non-treated bleeds. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

Time frame:
From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for All Bleeds
Percentage of participants1.5 mg/kg Emicizumab QW
ABR <172.3 (65.5 to 78.5)
ABR 1-3.420.5 (15.1 to 26.9)
ABR 3.5-104.6 (2.1 to 8.6)
ABR >102.6 (0.8 to 5.9)
SecondaryPercentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds

The number of bleeds over the efficacy period was calculated as an ABR for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds: treated bleeds with no other known contributing factor such as trauma or procedure/surgery. Bleeds due to surgery/procedure were excluded. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Included data before up-titration only, for participants whose dose was up-titrated.

Time frame:
From first dose of emicizumab until dose up-titration or withdrawal from treatment (median [min-max] efficacy period: 103.14 [1.1-108.3] weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds
Percentage of participants1.5 mg/kg Emicizumab QW
ABR <195.4 (91.4 to 97.9)
ABR 1-3.42.6 (0.8 to 5.9)
ABR 3.5-101.0 (0.1 to 3.7)
ABR >101.0 (0.1 to 3.7)
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Total Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. The Total Score is based on the scores for each domain and ranges from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Total Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit41.09 ± 16.15
Change from BL at Month 3-17.39 ± 12.86
Change from BL at Month 6-16.40 ± 14.58
Change from BL at Month 12-17.44 ± 14.16
Change from BL at Month 18-16.27 ± 15.39
Change from BL at Early Termination/Study Completion-14.13 ± 13.70
Statistical analysis
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
SecondaryPercentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Total Score at Specified Timepoints

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. The Total Score is based on the scores for each domain and ranges from 0 to 100, with lower scores reflective of better quality of life. An improvement larger than the responder threshold was defined as a decrease from baseline of at least 7 points in the Haem-A-QoL Total score.

Time frame:
At 3, 6, 12, and 18 months
Reported as:
Number · Percentage of participants
Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Total Score at Specified Timepoints
Percentage of participants1.5 mg/kg Emicizumab QW
Month 378.2
Month 672.4
Month 1270.8
Month 1869.9
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Physical Health Domain Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Physical Health Domain Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit51.13 ± 23.02
Change from BL at Month 3-27.36 ± 20.70
Change from BL at Month 6-26.10 ± 23.12
Change from BL at Month 12-25.21 ± 23.31
Change from BL at Month 18-23.14 ± 24.51
Change from BL at Early Termination/Study Completion-23.29 ± 25.16
Statistical analysis
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
SecondaryPercentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Physical Health Domain Score at Specified Timepoints

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life. An improvement larger than the responder threshold was defined as a decrease from baseline of at least 10 points in the Haem-A-QoL Physical Health domain score.

Time frame:
At 3, 6, 12, and 18 months
Reported as:
Number · Percentage of participants
Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Physical Health Domain Score at Specified Timepoints
Percentage of participants1.5 mg/kg Emicizumab QW
Month 379.6
Month 674.5
Month 1272.9
Month 1871.3
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Treatment Domain Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Treatment Domain Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit39.40 ± 19.89
Change from BL at Month 3-23.44 ± 22.07
Change from BL at Month 6-21.01 ± 23.74
Change from BL at Month 12-22.21 ± 22.57
Change from BL at Month 18-20.34 ± 25.37
Change from BL at Early Termination/Study Completion-21.16 ± 22.31
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Work and School Domain Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Work and School Domain Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit39.23 ± 25.31
Change from BL at Month 3-21.40 ± 26.51
Change from BL at Month 6-21.91 ± 27.17
Change from BL at Month 12-22.43 ± 25.55
Change from BL at Month 18-21.43 ± 26.65
Change from BL at Early Termination/Study Completion-18.83 ± 29.54
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Dealing With Hemophilia Domain Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Dealing With Hemophilia Domain Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit26.61 ± 19.76
Change from BL at Month 35.32 ± 30.06
Change from BL at Month 65.73 ± 28.14
Change from BL at Month 125.24 ± 29.18
Change from BL at Month 187.70 ± 29.75
Change from BL at Early Termination/Study Completion10.60 ± 33.42
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Feelings Domain Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Feelings Domain Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit36.25 ± 24.53
Change from BL at Month 3-21.22 ± 22.69
Change from BL at Month 6-20.88 ± 24.11
Change from BL at Month 12-22.37 ± 23.78
Change from BL at Month 18-19.55 ± 25.43
Change from BL at Early Termination/Study Completion-17.95 ± 23.62
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Family Planning Domain Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Family Planning Domain Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit25.64 ± 28.49
Change from BL at Month 3-8.64 ± 20.95
Change from BL at Month 6-9.07 ± 20.78
Change from BL at Month 12-10.83 ± 22.51
Change from BL at Month 18-12.39 ± 25.20
Change from BL at Early Termination/Study Completion-9.38 ± 24.81
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Future Domain Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Future Domain Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit42.70 ± 21.95
Change from BL at Month 3-15.56 ± 17.63
Change from BL at Month 6-15.46 ± 17.83
Change from BL at Month 12-14.46 ± 20.10
Change from BL at Month 18-14.43 ± 19.83
Change from BL at Early Termination/Study Completion-13.29 ± 19.56
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Partnership and Sexuality Domain Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Partnership and Sexuality Domain Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit23.17 ± 28.65
Change from BL at Month 3-7.35 ± 25.25
Change from BL at Month 6-6.03 ± 22.76
Change from BL at Month 12-7.74 ± 27.60
Change from BL at Month 18-9.72 ± 28.16
Change from BL at Early Termination/Study Completion-4.05 ± 21.32
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Sports and Leisure Domain Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Sports and Leisure Domain Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit68.86 ± 21.24
Change from BL at Month 3-19.65 ± 23.67
Change from BL at Month 6-17.63 ± 25.86
Change from BL at Month 12-22.56 ± 22.17
Change from BL at Month 18-20.20 ± 25.86
Change from BL at Early Termination/Study Completion-20.65 ± 28.65
SecondaryChange From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire View of Yourself Domain Score at Specified Timepoints, Adult Participants

The Haem-A-QoL questionnaire was designed for adult participants (greater than or equal to 18 years old) with hemophilia. It consists of 46 items comprising 10 domains: physical health, treatment, work and school, dealing with hemophilia, feelings, familly planning, future, partnerships and sexuality, sports and leisure, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always; although, for some items there is also a 'not applicable' option. Scale scores for each domain range from 0 to 100, with lower scores reflective of better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire View of Yourself Domain Score at Specified Timepoints, Adult Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit43.57 ± 22.05
Change from BL at Month 3-13.51 ± 20.63
Change from BL at Month 6-15.04 ± 21.19
Change from BL at Month 12-15.71 ± 19.88
Change from BL at Month 18-15.19 ± 21.88
Change from BL at Early Termination/Study Completion-9.50 ± 20.70
SecondaryChange From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score at Specified Timepoints, Adolescent Participants

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. The Total Score is derived from the scores for all domains and scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score at Specified Timepoints, Adolescent Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit35.10 ± 12.42
Change from BL at Month 3-9.60 ± 12.51
Change from BL at Month 6-12.65 ± 12.72
Change from BL at Month 12-13.57 ± 13.20
Change from BL at Month 18-14.02 ± 11.83
Change from BL at Early Termination/Study Completion-18.37 ± 17.53
Statistical analysis
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = 0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = 0.0004
SecondaryPercentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score at Specified Timepoints

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. The Total Score is derived from the scores for all domains and scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life. An improvement larger than the responder threshold was defined as a decrease of at least 5 points in the Haemo-QoL-SF Total score.

Time frame:
At 3, 6, 12, and 18 months
Reported as:
Number · Percentage of participants
Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score at Specified Timepoints
Percentage of participants1.5 mg/kg Emicizumab QW
Month 363.9
Month 675.7
Month 1275.0
Month 1869.2
SecondaryChange From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Physical Health Domain Score at Specified Timepoints, Adolescent Participants

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Physical Health Domain Score at Specified Timepoints, Adolescent Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit42.14 ± 18.40
Change from BL at Month 3-29.10 ± 20.12
Change from BL at Month 6-29.78 ± 17.55
Change from BL at Month 12-30.47 ± 20.74
Change from BL at Month 18-30.71 ± 18.83
Change from BL at Early Termination/Study Completion-34.03 ± 25.66
Statistical analysis
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
SecondaryPercentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Physical Health Domain Score at Specified Timepoints

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life. An improvement larger than the responder threshold was defined as a decrease of at least 10 points in the Haemo-QoL-SF Physical Health domain score.

Time frame:
At 3, 6, 12, and 18 months
Reported as:
Number · Percentage of participants
Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Physical Health Domain Score at Specified Timepoints
Percentage of participants1.5 mg/kg Emicizumab QW
Month 377.8
Month 678.4
Month 1275.0
Month 1879.5
SecondaryChange From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Treatment Domain Score at Specified Timepoints, Adolescent Participants

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Treatment Domain Score at Specified Timepoints, Adolescent Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit31.61 ± 18.12
Change from BL at Month 3-9.38 ± 20.94
Change from BL at Month 6-8.64 ± 23.23
Change from BL at Month 12-10.74 ± 21.31
Change from BL at Month 18-12.68 ± 21.68
Change from BL at Early Termination/Study Completion-20.83 ± 23.87
SecondaryChange From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Sports and School Domain Score at Specified Timepoints, Adolescent Participants

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Sports and School Domain Score at Specified Timepoints, Adolescent Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit62.32 ± 21.30
Change from BL at Month 3-15.82 ± 25.55
Change from BL at Month 6-20.04 ± 29.27
Change from BL at Month 12-22.07 ± 26.71
Change from BL at Month 18-28.21 ± 27.80
Change from BL at Early Termination/Study Completion-23.61 ± 28.16
SecondaryChange From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Dealing With Hemophilia Domain Score at Specified Timepoints, Adolescent Participants

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Dealing With Hemophilia Domain Score at Specified Timepoints, Adolescent Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit24.11 ± 14.79
Change from BL at Month 3-7.23 ± 18.25
Change from BL at Month 6-7.72 ± 17.75
Change from BL at Month 12-10.35 ± 20.24
Change from BL at Month 18-3.39 ± 25.70
Change from BL at Early Termination/Study Completion-12.50 ± 23.48
SecondaryChange From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Feelings Domain Score at Specified Timepoints, Adolescent Participants

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Feelings Domain Score at Specified Timepoints, Adolescent Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit26.43 ± 25.10
Change from BL at Month 3-9.57 ± 20.08
Change from BL at Month 6-16.36 ± 21.54
Change from BL at Month 12-13.09 ± 22.80
Change from BL at Month 18-15.18 ± 25.51
Change from BL at Early Termination/Study Completion-23.96 ± 32.67
SecondaryChange From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Family Domain Score at Specified Timepoints, Adolescent Participants

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Family Domain Score at Specified Timepoints, Adolescent Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit46.07 ± 20.79
Change from BL at Month 3-6.84 ± 15.66
Change from BL at Month 6-11.95 ± 20.84
Change from BL at Month 12-14.84 ± 23.32
Change from BL at Month 18-15.36 ± 21.67
Change from BL at Early Termination/Study Completion-15.28 ± 19.08
SecondaryChange From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Friends Domain Score at Specified Timepoints, Adolescent Participants

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Friends Domain Score at Specified Timepoints, Adolescent Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit35.95 ± 26.02
Change from BL at Month 3-0.52 ± 24.95
Change from BL at Month 6-3.19 ± 28.13
Change from BL at Month 12-5.47 ± 27.57
Change from BL at Month 18-5.95 ± 36.41
Change from BL at Early Termination/Study Completion-7.41 ± 31.56
SecondaryChange From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Other People Domain Score at Specified Timepoints, Adolescent Participants

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Other People Domain Score at Specified Timepoints, Adolescent Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit21.43 ± 17.50
Change from BL at Month 3-2.93 ± 18.72
Change from BL at Month 6-5.51 ± 19.08
Change from BL at Month 12-8.01 ± 18.53
Change from BL at Month 18-6.79 ± 17.51
Change from BL at Early Termination/Study Completion-11.81 ± 18.55
SecondaryChange From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire View of Yourself Domain Score at Specified Timepoints, Adolescent Participants

The Haemo-QoL-SF was designed as a series of age-related questionnaires to measure health-related quality of life in children and adolescents (12-17 year olds) with hemophilia. This version contains 35 items and covers nine domains considered relevant for children's health-related quality of life: physical health, treatment, sports and school, dealing with hemophilia, feelings, family, friends, other people, and view of yourself. Items are rated by participants with one of five response options: never, seldom, sometimes, often, and always. Scale scores range from 0 to 100, with a lower score reflective of better health-related quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire View of Yourself Domain Score at Specified Timepoints, Adolescent Participants
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit26.07 ± 22.04
Change from BL at Month 3-2.73 ± 26.03
Change from BL at Month 6-8.27 ± 23.27
Change from BL at Month 12-5.08 ± 24.82
Change from BL at Month 18-5.89 ± 21.54
Change from BL at Early Termination/Study Completion-13.19 ± 26.59
SecondaryChange From Baseline in the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) Index Utility Score at Specified Timepoints

The EQ-5D-5L is a generic, self-reported, preference-based health utility measure that consists of six questions and is used to assess health status and inform pharmacoeconomic evaluations. The index utility score is based on the participant's assessment of their health on five scales: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It ranges from -0.224 to 1, with 0 corresponding to death and 1 corresponding to full health; negative values correspond to health states worse than death. Higher scores indicate better quality of life.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) Index Utility Score at Specified Timepoints
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit0.67 ± 0.23
Change from BL at Month 30.08 ± 0.18
Change from BL at Month 60.11 ± 0.18
Change from BL at Month 120.09 ± 0.19
Change from BL at Month 180.07 ± 0.21
Change from BL at Early Termination/Study Completion0.10 ± 0.22
Statistical analysis
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
SecondaryChange From Baseline in the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) Quality-of-Life Visual Analogue Scale (VAS) Score at Specified Timepoints

The EQ-5D-5L is a generic, self-reported, preference-based health utility measure that consists of six questions and is used to assess health status and inform pharmacoeconomic evaluations. The visual analogue scale (VAS) ranges from 0 to 100 points, on which the participant self-assesses their current health status; 0 being the worst health you can imagine and 100 being the best health you can imagine. Higher scores are reflective of better health.

Time frame:
Baseline (Week 1), 3, 6, 12, and 18 months, and at Early Termination or Study Completion (up to 24 months)
Reported as:
Mean · score on a scale
Change From Baseline in the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) Quality-of-Life Visual Analogue Scale (VAS) Score at Specified Timepoints
score on a scale1.5 mg/kg Emicizumab QW
Baseline (BL) - Value at Visit71.01 ± 19.41
Change from BL at Month 38.02 ± 18.70
Change from BL at Month 610.27 ± 17.24
Change from BL at Month 1210.69 ± 18.18
Change from BL at Month 189.49 ± 21.08
Change from BL at Early Termination/Study Completion14.52 ± 17.91
Statistical analysis
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
  • 1.5 mg/kg Emicizumab QW · Paired t-test · p = <0.0001
SecondaryPercentage of Participants Who Preferred the New Emicizumab Treatment or the Old Hemophilia Treatment, or Without Treatment Preference, as Assessed by the EmiPref Questionnaire

The EmiPref questionnaire asked participants to specify the treatment they would prefer to continue to receive after receiving treatment with their previous episodic or prophylactic regimen and subcutaneous (SC) emicizumab, or if they had no preference. The 95% confidence intervals were calculated for one sample binomial using the Pearson-Clopper method.

Time frame:
Month 3
Reported as:
Number · Percentage of participants
Percentage of Participants Who Preferred the New Emicizumab Treatment or the Old Hemophilia Treatment, or Without Treatment Preference, as Assessed by the EmiPref Questionnaire
Percentage of participants1.5 mg/kg Emicizumab QW
Prefer the New Study Drug Treatment (Emicizumab)96.6 (92.85 to 98.76)
Prefer my Old Hemophilia Treatment0.6 (0.01 to 3.07)
Have no Preference2.8 (0.91 to 6.40)
SecondaryNumber and Percentage of Participants With Anti-Drug Antibodies (ADAs) Against Emicizumab at Anytime Post-Baseline

'Total ADA Negative' is the sum of all subjects who tested negative for ADA in the 2 following categories: 'ADA Negative', those who are pre-dose ADA negative or are missing pre-dose ADA data and who have all negative post-dose ADA results; and 'ADA Negative (Treatment Unaffected)', a subset who are pre-dose ADA positive but do not have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample.

Time frame:
Baseline (Week 1), Week 5, and at 3, 6, 9, 12, and 18 months, and at early termination/study completion (up to 24 months)
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) Against Emicizumab at Anytime Post-Baseline
Participants1.5 mg/kg Emicizumab QW
Total ADA Negative (Neg + Neg Unaffected)183
ADA Negative180
ADA Negative (Treatment Unaffected)3
Total ADA Positive (Boosted + Induced)10
ADA Positive (Treatment Boosted)2
ADA Positive (Treatment Induced)8
SecondaryMean Trough Plasma Concentrations of Emicizumab at Specified Timepoints

The trough concentration is a measure of the plasma concentration of a study drug at the end of of the dosage interval.

Time frame:
Pre-dose at Weeks 2, 3, and 5, Months 3, 6, 12, and 18, and at treatment discontinuation (up to 2 years)
Reported as:
Mean · micrograms per millilitre (μg/mL)
Mean Trough Plasma Concentrations of Emicizumab at Specified Timepoints
micrograms per millilitre (μg/mL)1.5 mg/kg Emicizumab QW
Week 216.7 ± 5.5
Week 330.7 ± 9.2
Week 552.4 ± 15.5
Month 352.5 ± 18.3
Month 653.4 ± 19.3
Month 1254.2 ± 20.6
Month 1853.6 ± 18.3
Treatment Discontinuation54.6 ± 19.0

Adverse events

Collected over From Baseline until study completion (up to 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.5 mg/kg Emicizumab QW2/193 (1%)31/193 (16.1%)104/193 (53.9%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
Event1.5 mg/kg Emicizumab QW
CATHETER SITE ABSCESSInfections and infestations2/193
FEMUR FRACTUREInjury, poisoning and procedural complications2/193
WOUND DEHISCENCEInjury, poisoning and procedural complications2/193
HAEMATOMA MUSCLEMusculoskeletal and connective tissue disorders2/193
THROMBOCYTOPENIABlood and lymphatic system disorders1/193
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/193
ABDOMINAL COMPARTMENT SYNDROMEGastrointestinal disorders1/193
DIVERTICULUM INTESTINAL HAEMORRHAGICGastrointestinal disorders1/193
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/193
RETROPERITONEAL HAEMATOMAGastrointestinal disorders1/193
Most frequent other events
Most frequent other events
Event1.5 mg/kg Emicizumab QW
ARTHRALGIAMusculoskeletal and connective tissue disorders33/193
NASOPHARYNGITISInfections and infestations30/193
HEADACHENervous system disorders29/193
INJECTION SITE REACTIONGeneral disorders22/193
PYREXIAGeneral disorders21/193
INFLUENZAInfections and infestations16/193
FALLInjury, poisoning and procedural complications12/193
COUGHRespiratory, thoracic and mediastinal disorders12/193
LIMB INJURYInjury, poisoning and procedural complications10/193

Baseline characteristics

Age, Continuous
Age, Continuous(Years)1.5 mg/kg Emicizumab QW
Mean32.2 ± 16.6
Age, Customized
Age, Customized(Participants)1.5 mg/kg Emicizumab QW
≥12 to <18 Years Old40
≥18 to <65 Years Old146
≥65 Years Old9
Sex: Female, Male
Sex: Female, Male(Participants)1.5 mg/kg Emicizumab QW
Female0
Male195
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1.5 mg/kg Emicizumab QW
Hispanic or Latino41
Not Hispanic or Latino143
Unknown or Not Reported11
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.5 mg/kg Emicizumab QW
American Indian or Alaska Native19
Asian38
Native Hawaiian or Other Pacific Islander1
Black or African American7
White121
More than one race0
Unknown or Not Reported9
08

Study locations

72 sites
  • Royal Prince Alfred Hospital; Haematology
    Camperdown, New South Wales 2050, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Centro de Hematologia E Hemoterapia Do Parana - Hemepar
    Curitiba, PR 80045-145, Brazil
  • Instituto Estadual de Hema
    Rio de Janeiro, RJ 20211-030, Brazil
  • Hospital das Clinicas - UNICAMP
    Campinas, SP 13083-888, Brazil
  • Faculdade de Medicina de Ribeirão Preto - Universidade de Sao Paulo
    Ribeirao Preto, SP 14051-140, Brazil
  • Kaye Edmonton Clinic
    Edmonton, Alberta T6G 2V2, Canada
  • CancerCare Manitoba; Neuro-Oncology
    Winnipeg, Manitoba R2H 2A6, Canada
  • McMaster University Health Sciences Center
    Hamilton, Ontario L8N 3Z5, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Centro de Atención e Investigación Médica CAIMED S.A.S
    Localidad Puente Aranda, 111611, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, 050034, Colombia
  • Helsingin yliopistollinen keskussairaala, Meilahden sairaala
    Helsinki, 00290, Finland
  • Vivantes Klinikum im Friedrichshain - Landsberger Allee, Angiologie und Hämostaseologie
    Berlin, 10249, Germany
  • Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin
    Bonn, 53127, Germany
  • Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin; Johann Wolfgang Goethe-Univers.
    Frankfurt/M., 60590, Germany
  • Universitätsklinikum Leipzig, Innere Medizin, Neurologie, Dermatologie; Zentrum für Hämostaseologie
    Leipzig, 04103, Germany
  • Hämophilie-Zentrum Rhein Main GmbH
    Mörfelden-Walldorf, 64546, Germany
  • Klinikum der Universität München, Campus Innenstadt; Hämostaseologische Ambulanz/Hämophiliezentrum
    München, 80336, Germany
  • Oncomedica
    Guatemala, 01010, Guatemala
  • Magyar Honvédség Egészségügyi Központ; Országos Haemophilia Központ
    Budapest, 1134, Hungary
  • Országos Vérellátó Szolgálat - Győri Regionális Vérellátó Központ
    Győr, 9023, Hungary
  • University of Pecs, I st Dept of Internal Medicine
    Pecs, 7624, Hungary
  • St. John's Medical College & Hospital; Department of Medicine
    Bengaluru, Karnataka 560034, India
  • King Edward Memorial Hospital and Seth G.S. Medical College; Department of Hematology
    Mumbai, Maharashtra 400012, India
  • Fortis Hospitals Limited
    Mumbai, Maharashtra 400078, India
  • Sahyadri Speciality Hospital; Hematology & Bone Marrow Unit
    Pune, Maharashtra 411004, India
  • Christian Medical College & Hospital; Department of Haematology
    Vellore, Maharashtra 632004, India
  • Nil Ratan Sircar Medical College and Hospital; Department of Hematology
    Kolkata, WEST Bengal 700014, India
  • Grant Medical Foundation, Ruby Hall Clinic
    Pune, 411001, India
  • Sheba Medical Center - National Hemophilia Center
    Tel Hashomer, 5262100, Israel
  • AOU Federico II; Medicina Clinica Chirurgia Centro Emocoaugulopatie e Emofilia
    Napoli, Campania 80131, Italy
  • AOU Policlinico S. Orsola Malpighi; U.O. Angiologia e Malattie della Coagulazione Marino Golinelli
    Bologna, Emilia-Romagna 40138, Italy
  • AOU di Parma; Dip Emergenza-Urgenza Centro Riferimento Regionale per l'emofilia
    Parma, Emilia-Romagna 43126, Italy
  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol
    Roma, Lazio 00161, Italy
  • IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"
    Milano, Lombardia 20122, Italy
  • AO Città Salute e Scienza D-Osp S. G. Battista Molinette; SSCVD Malattie Tromboti e Emorragiche
    Torino, Piemonte 10126, Italy
  • Azienda Uni Ria Policlinico P. Giaccone ; Divisione Di Ematologia E Trapianto
    Palermo, Sicilia 90127, Italy
  • AOU Careggi; SOD Malattie Emorragiche
    Firenze, Toscana 50134, Italy
  • Azienda Ospedaliera di Padova; Centro Emofilia
    Padova, Veneto 35128, Italy
  • Hospital General de México
    Distrito Federal, Mexico CITY (federal District) 06726, Mexico
  • CENTRO MEDICO NACIONAL SIGLO XXI; Banco de Sangre
    Mexico City, Mexico CITY (federal District) 06720, Mexico
  • Hospital de Especialidades Centro Medico Nacional La Raza; Haematology
    Mexico City, 02990, Mexico
  • Erasmus MC / location Sophia Kinderziekenhuis
    Rotterdam, 3015 GJ, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Complejo Hospitalario Arnulfo Arias Madrid; Servicio de Hematología
    Panama City, 0824, Panama
  • Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych
    Warsaw, 02-776, Poland
  • Hospital Geral; Servico de Imuno-Hemoterapia
    Coimbra, 3041-853, Portugal
  • Hospital de Santa Maria; Servico de Imuno-Hemoterapia; Servico de Imuno-Hemoterapia
    Lisboa, 1649-035, Portugal
  • Hospital de Sao Joao; Servico de Imuno-Hemoterapia; Servico de Imuno-Hemoterapia
    Porto, 4200-319, Portugal
  • Louis Turcanu Emergency Clinical Hospital for Children; First Pediatric Clinic
    Timisoara, 300011, Romania
  • Regional State Budgetary Institution of Healthcare "Regional Cinilcal Hospital"; Pulmonology
    Barnaul, Altaj 656024, Russian Federation
  • Morozov Children's Municipal Clinical Hospital. Haematology department
    Moscow, 119049, Russian Federation
  • "Hematological Scientific Center
    Moscow, 125167, Russian Federation
  • City Outpatient Clinic #37, City Hemophilia Treatment Center
    Saint Petersburg, 191186, Russian Federation
  • Samara State Medical University
    Samara, 443099, Russian Federation
  • King Faisal Specialist Hospital & Research Centre; Oncology
    Riyadh, 11211, Saudi Arabia
  • Hospital Universitario Vall de Hebron; Unidad de Hemofília
    Barcelona, 08035, Spain
  • Hospital Universitario la Paz; Servicio de Hematologia
    Madrid, 28046, Spain
  • Hospital Regional Universitario Carlos Haya; Servicio de Hematologia
    Malaga, 29010, Spain
  • Hospital Universitario Virgen del Rocio; Servicio de Hematologia
    Sevilla, 41013, Spain
  • Hospital Universitario la Fe; Servicio de Hematologia
    Valencia, 46026, Spain
  • Sahlgrenska Universitetssjukhuset; Koagulationscentrum
    Göteborg, 413 45, Sweden
  • Karolinska Universitetssjukhuset; Koagulationsmottagningen
    Solna, 171 64, Sweden
  • Inselspital Bern; Hämatologie und Hämatologisches Zentrallabor
    Bern, 3010, Switzerland
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B15 2TH, United Kingdom
  • The Royal London Hospital
    London, E1 2ES, United Kingdom
  • Royal Free Hospital
    London, NW3 2QS, United Kingdom
  • Royal Victoria Infirmary; Non-Malignant Haematology Research
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Foundation Trust
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2020, 38 months.

Results were first posted in Jun 2021, 6 months after primary completion.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 38 months is above that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2017
First posted
Jun 19, 2017
StartActual
Sep 5, 2017
Primary completionActual
Nov 19, 2020
CompletionActual
Nov 19, 2020
Results first posted
Jun 11, 2021
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03191799
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 19, 2017
Start date
Sep 5, 2017
Primary completion
Nov 19, 2020
Completion
Nov 19, 2020
Results posted
Jun 11, 2021
Last update
Jun 11, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emicizumab

Start the discussion